Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin, 1111 Highland Avenue, Room 4031, Madison, WI 53705, USA.
Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
Hematol Oncol Clin North Am. 2020 Oct;34(5):971-982. doi: 10.1016/j.hoc.2020.06.011. Epub 2020 Aug 5.
Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients' health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients' lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.
套细胞淋巴瘤（MCL）是一种独特的淋巴瘤，其临床病程具有异质性，且缺乏共识性的治疗方法。MCL 通常在确诊时采用免疫化疗，在复发时采用慢性治疗。尽管治疗取得了显著进展，但 MCL 仍无法治愈。维持患者的健康相关生活质量（HRQOL）是一个重要的治疗目标。HRQOL 评估阐明了疾病及其治疗对患者生活的影响。本综述强调了 HRQOL 评估在 MCL 中的相关性，评估了现有证据、当前 HRQOL 评估中的知识空白和挑战，并确定了改善 MCL 患者 HRQOL 评估的未来方向。
